Time to post-remission therapy is an independent prognostic factor in adults with acute lymphoblastic leukemia

References

• Yanada M, Matsuo K, Suzuki T, Naoe T. Allogeneic hematopoietic stem cell transplantation as part of postremission therapy improves survival for adult patients with high-risk acute lymphoblastic leukemia: a metaanalysis. Cancer 2006; 106: 2657–2663
   PubMed Web of Science ®Google Scholar
• Hoelzer D, Theil E, Loffler H, Buchner T, Ganser A, Heil G, et al. Prognostic factors in a multicenter study for treatment of acute lymphoblastic leukemia in adults. Blood 1988; 71: 123–131
   PubMed Web of Science ®Google Scholar
• Wetzler M, Dodge R K, Mrozek K, Carroll A J, Tantravahi R, Block A W, et al. Prospective karyotype analysis in adult acute lymphoblastic leukemia: the Cancer and Leukemia Group B Experience. Blood 1999; 93: 3983–3993
   PubMed Web of Science ®Google Scholar
• Bruggemann M, Raff T, Flohr T, Gokbuget N, Nakao M, Droese J, et al. Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia. Blood 2006; 107: 1116–1123
   PubMed Web of Science ®Google Scholar
• Plasschaert S L, deBont E S, Boezen M, vander Kolk D M, Daenen S M, Faber K N, et al. Expression of multidrug resistance-associated proteins predicts prognosis in childhood and adult acute lymphoblastic leukemia. Clin Cancer Res 2005; 11: 8661–8668
   PubMed Web of Science ®Google Scholar
• Zhu Y M, Zhao W L, Fu J F, Shi J Y, Pan Q, Hu J, et al. NOTCH1 mutations in T-cell acute lymphoblastic leukemia: prognostic significance and implications in multifactorial leukemogenesis. Clin Cancer Res 2006; 12: 3043–3049
   PubMed Web of Science ®Google Scholar
• Cario G, Stanulla M, Fine B M, Teuffel O, Neuhoff N V, Schrauder A, et al. Distinct gene expression profiles determine molecular treatment response in childhood acute lymphoblastic leukemia. Blood 2005; 105: 821–826
   PubMed Web of Science ®Google Scholar
• Larson R A, Dodge R K, Burns C P, Lee E J, Stone R M, Schulman P, et al. A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and Leukemia Group B Study 8111. Blood 1995; 85: 2025–2037
   PubMed Web of Science ®Google Scholar
• Stock W, Johnson J, Yu D, Bennett D, Sher D, Stone R M, et al. Daunorubicin dose intensification during treatment of adult acute lymphoblastic leukemia (ALL): final results from CALGB 19802. American Society of Hematology, Atlanta, GA, December, 10–132005, Abstract 833
   Google Scholar
• Weiss M A, Heffner L, Lamanna N, Kalaycio M, Schiller G, Coutre S, et al. A randomized trial demonstrating the superiority of cytarabine with high-dose mitoxantrone compared to a standard vincristine/prednisone-based regimen as induction therapy in patients with acute lymphoblastic leukemia. American Society of Clinical Oncology. Orlando, FL 2005; 13–17, Abstract 6516
   Google Scholar
• Gaynor J, Chapman D, Little C, McKenzie S, Miller W, Andreef M, et al. A cause-specific hazard rate analysis of prognostic factors among 199 adults with acute lymphoblastic leukemia: The Memorial Hospital experience since 1969. J Clin Oncol 1988; 6: 1014–1030
   PubMed Web of Science ®Google Scholar
• Clarkson B D, Gee T, Alrin Z A, Mertelsmann R, Kempin S J, Dinsmore R E, et al. Current status of treatment of acute leukemia in adults: an overview of the Memorial experience and review of literature. Crit Rev Oncol Hematol 1986; 4: 221–248
   PubMed Web of Science ®Google Scholar
• Hoelzer D, Gokbuget N. Acute lymphoblastic leukemia in adults. Leukemia, E S Henderson, T A Lister, M F Greaves. Saunders, Philadelphia, London, New York, St. Louis, Syndney, Toronto 2002; 621–656
   Google Scholar
• Dworzak M N, Froschl G, Printz D, Mann G, Potschger U, Muhlegger N, et al. Prognostic significance and modalities of flow cytometry minimal residual disease detection in childhood acute lymphoblastic leukemia. Blood 2002; 99: 1952–1958
   PubMed Web of Science ®Google Scholar
• Boissel N, Auclerc M F, Lheritier V, Perel Y, Thomas X, Leblanc T, et al. Should adolescents with acute lymphoblastic leukemia be treated as children or young adults: comparison of the French FRALLE-93 and LALA-94. J Clin Oncol 2003; 21: 774–780
   PubMed Web of Science ®Google Scholar
• Rowe J M, Buck G, Fielding A, Tallman M, Burnett A K, Chopra R, et al. In adults with standard-risk acute lymphoblastic leukemia (ALL), the greatest benefit is achieved from an allogeneic transplant in first CR and an autologous transplant is less effective than conventional consolidation/maintenance chemotherapy: final results of the international ALL trial (MRC UKALL XII/ECOG E2993). American Society of Hematology, Orlando, FL, December, 9–122006, Abstract 2
   Google Scholar